Compare · NVO vs SDEV
NVO vs SDEV
Side-by-side comparison of Novo Nordisk A/S (NVO) and Stablecoin Development Corporation (SDEV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SDEV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $181.94B, about 2950.6x SDEV ($61.7M).
- Over the past year, NVO is down 18.2% and SDEV is down 84.6% - NVO leads by 66.4 points.
- SDEV has been more active in the news (8 items in the past 4 weeks vs 7 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for SDEV).
- Company
- Novo Nordisk A/S
- Stablecoin Development Corporation
- Price
- -
- -
- Market cap
- $181.94B
- $61.7M
- 1M return
- +8.00%
- -32.74%
- 1Y return
- -18.24%
- -84.62%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 7
- 8
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SDEV
- Director Sit Swan converted options into 6,177 shares, increasing direct ownership by 61,770% to 6,187 units (SEC Form 4)
- Director Freiman Paul E. converted options into 6,177 shares, increasing direct ownership by 56,155% to 6,188 units (SEC Form 4)
- Director Zheng Yenyou converted options into 6,177 shares, increasing direct ownership by 61,770% to 6,187 units (SEC Form 4)
- Highway Holdings Limited Announces Closing of $7.0 Million Strategic Investment by David Lazar and Planned Spin-Off of Its Legacy Business to Existing Shareholders
- SEC Form 8-K filed by Stablecoin Development Corporation
- Stablecoin Development Corporation Reports Third Quarter 2026 Financial Results
- SEC Form 10-Q filed by Stablecoin Development Corporation
- Amendment: SEC Form S-3/A filed by Stablecoin Development Corporation
- Amendment: SEC Form S-3/A filed by Stablecoin Development Corporation
- Stablecoin Development Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits